Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis
NfL is the most validated biomarker for ALS diagnosis and prognosis, in both blood and CSF. However, its limited accuracy when used alone carries a considerable risk of misclassification. Future studies should adopt prevalence-specific strategies and integrate biomarkers within multimodal frameworks to enhance diagnostic and prognostic precision.
Authors
- Masahisa Katsuno (ORCID: https://orcid.org/0000-0001-9453-9311)
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Alexander Santillo (ORCID: https://orcid.org/0000-0001-9717-0820)
- Daisuke Ito (ORCID: https://orcid.org/0000-0002-5037-2289)
- Christer Nilsson (ORCID: https://orcid.org/0000-0002-6517-4453)
- Shorena Janelidze
- Kazuki Obara (ORCID: https://orcid.org/0009-0006-5170-9169)
Institutions
- Lund University (SE)
- Skåne University Hospital (SE)
- Nagoya University (JP)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1111/ene.70382
- Citations
- 4
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- Alzheimer's Association
- Eli Lilly and Company
- Australian Government
- Ministry of Education, Culture, Sports, Science and Technology
- Lunds Universitet
- Vetenskapsrådet
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Japan Science and Technology Agency
- Medicinska Fakulteten, Lunds Universitet